News

SAN ANTONIO, TEXAS – Andrew Hoover has been named Associate Vice President and Portfolio Manager for Fountainhead Investment Partners. In this role, Hoover will implement the firm’s investment strategy while expanding the firm’s research capabilities and developing new funds for investment partners. In addition, Hoover will support Fountainhead portfolio companies in various finance roles.

Hoover is also the CFO for AmnioLife Corporation, a Fountainhead portfolio company, where he was a founding member of the management team and instrumental in closing the Series A funding round for the company.

Hoover has more than nine years of experience in finance and investments. His expertise spans corporate finance, equity valuation, credit analysis, and venture debt underwriting. Prior to working with AmnioLife, he held positions at Square 1 Bank, RS Investments and Oak Value Capital Management.
 
“Fountainhead is growing at such a pace that having someone of Andrew’s expertise as part of the team is essential,” said Brian Kieser, Managing Partner of Fountainhead Investment Partners. “In 2016, we are on target to increase the size of our funds and expand our investments. Andrew will be instrumental in that process as well as supporting our portfolio companies in their growth initiatives.”

Fountainhead Investment Partners is focusing its initial investments in areas of medical devices, surgical tools, multicellular biologics, regenerative technologies, medical knowledge management and 3D printing. Investments ranging from $250,000 to $1.5 million will be made in early-stage companies with the vision of connecting advancing technologies in order to solve some of medicines’ most complex issues.

About Fountainhead Investment Partners
Fountainhead Investment Partners is a venture capital firm, based in San Antonio, Texas, that invests in early-stage companies. Fountainhead was originally founded as an angel fund in 2014 by a group of successful healthcare entrepreneurs with a vision to connect advancing technologies in order to solve some of medicines’ most complex issues.

In 2015, Fountainhead transitioned to a venture capital firm, with initial funds focused on companies that are accessing innovative technologies from all industries and applying them to the science of medicine with the intention of disrupting the industry while also advancing patient care.

Fountainhead makes portfolio investments ranging from $250,000 to $1.5 million.  Partners work side-by-side with portfolio companies on operations strategies and management guidance in order to maximize the highest potential growth.

Media Contact:
Bonnie Caver


Reputation Lighthouse

512-832-8588